Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai Huaota Biopharmaceutical Co., Ltd., has successfully raised RMB 200 million (USD 27.4 million) through a new issuance of 20 million shares. The shares were exclusively subscribed by Linhai Haijing Venture Capital. This transaction has increased Huaota Bio’s market capitalization to RMB 3.2 billion (USD 438.4 million).
Huaota Bio’s Product Pipeline and Future Prospects
Since its inception in 2013, Huaota Bio has established a rich product pipeline that includes monoclonal antibodies, bispecific antibodies, fusion proteins, and antibody drug conjugates (ADCs). The company’s pipeline is a testament to its commitment to innovation in the biopharmaceutical sector. Among its pipeline, one product is anticipated to be slated for marketing approval within the next three years, highlighting the potential for significant growth and market impact.-Fineline Info & Tech
